DNDi E-news
October 2015  |  View Online

DNDi Unveils New Plan for Neglected Patients

Aims to Deliver 16-18 Treatments for Up to 10 Diseases with EUR 650 Million

DNDi recently presented its plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. This plan paves the way for new diseases to be taken up in DNDi’s portfolio. As part of its updated Business Plan for the period 2015-2023, DNDi remains committed to developing treatments for African sleeping sickness, leishmaniasis, and Chagas disease as well as filarial diseases and paediatric HIV. Having recently transferred its malaria activities to the Medicines for Malaria Venture (MMV), DNDi will soon be launching new research and development (R&D) projects for hepatitis C and mycetoma, two very different diseases that share, with other important global health issues such as anti-microbial resistance, one key challenge: the existing system of biomedical innovation has failed to deliver safe, effective, quality products that are affordable to poor populations. »

DNDi awarded USD 2.34 million from new pooled fund mechanism at WHO-TDR

DNDi has been awarded USD 2.34 million for a large-scale leishmaniasis R&D project from a new pooled fund set up by Member States of the WHO. The ‘Leishmaniasis Global R&D and Access Initiative’ aims to demonstrate that R&D for can be incentivized and optimized through various mechanisms to fill R&D gaps. »

First single-dose oral drug candidate for sleeping sickness ready for testing in patients

After the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed by DNDi from the earliest drug discovery stage to combat sleeping sickness, DNDi and partners will start a pivotal Phase II/III trial in 2016 in the Democratic Republic of the Congo. »

DNDi lauds 2015 Nobel Prize winners for key advancements in malaria, river blindness, and lymphatic filariasis and calls for more to be done

DNDi applauds the three winners of the ‘2015 Nobel Prize in Physiology or Medicine’, whose research ultimately led to therapies for the highly debilitating parasitic worm diseases, lymphatic filariasis and river blindness, and the world’s largest parasitic killer, malaria. DNDi hopes it will encourage greater public leadership in innovation and access to treatments for neglected patients. »

New drug candidate to enter an otherwise empty pipeline for eumycetoma

DNDi and Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai’s anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world’s most neglected diseases. »

Mycetoma Close-up

A little-known, but devastating disease

Most probably transmitted through pricks to the skin by walking barefoot, eumycetoma is a chronic condition that affects people in tropical and subtropical regions, in particular across Africa, with the highest burden found in Sudan. The fungus penetrates the skin and causes massive tumour-like lesions that lead to serious disability, grave socioeconomic consequences, and stigma. Nineteen years ago, while playing on the school field, Alsadik Mohamed Musa Omer pricked his foot on a thorn. Like any other 15 year old boy, he continued playing…

Scientific Articles

PLOS Neglected Tropical Diseases:
Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study »

PLOS Neglected Tropical Diseases:
Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of leishmanicidal intracellular activity »

European Journal of Medicinal Chemistry:
Aminothiazoles: Hit to lead development to identify antileishmanial agents »

BioMed Central Medicine:
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data »

The Journal of Molecular Diagnostics:
Analytical validation of quantitative real-time PCR methods for quantification of Trypanosoma cruzi DNA in blood samples from Chagas disease patients »

BioMed Central Medicine:
Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data »

PLOS Neglected Tropical Diseases:
A review: The current in vivo models for the discovery and utility of new antileishmanial drugs targeting cutaneous leishmaniasis »

Bioorganic Medicinal Chemistry:
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation »

Drug Design, Development and Therapy:
Translational challenges of animal models in Chagas disease drug development: A review »

Antiprotozoal activity profiling of approved drugs: A starting point toward drug repositioning »

Benznidazole/itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease »

PLOS Neglected Diseases:
Target Product Profile (TPP) for Chagas disease point-of-care diagnosis and assessment of response to treatment »

Photo credits:
DNDi/Don Paul, DNDi/Benoît Marquet
DNDi Revela Nuevo Plan de pacientes Desatendidos »
DNDi recibió US$ 2,34 millones para la Leishmaniasis »
Reunión Anual de la Plataforma de Investigación Clinica en Enfermedad de Chagas 2015 »

DNDi Apresenta Novo Plano de Negócios para pacientes negligenciados »
DNDi Recebe Verba de US$ 2,34 Milhões para Leishmanioses »
Reunião da Plataforma de Pesquisa Clínica em Doença de Chagas »


World Health Summit
Berlin, 11-13 October 2015

ASTMH 2015
25-29 October 2015


33rd International Scientific Council for Trypanosomiasis Research and Control
N'djamena, 14-18 September 2015

Basel, 6-10 September 2015


Le Monde: 'Un Nobel de médecine à la portée très politique'

Estadão: 'Especialista em doenças negligenciadas celebra resultado do Nobel'

Business Standard: 'DNDi lauds Nobel winners for advances in neglected disease research'

Tages Anzeiger: 'Im Kampf gegen Malaria und Fadenwürmer'

The Conversation: 'Combating ‘neglected’ diseases using nature’s apothecary'

Le Temps: 'Un Nobel pour les médecines tropicales'

Diário do Nordeste: 'Nobel vai para estudos de malária e verminose'

Forbes: 'Chagas: An Emerging Disease Threat in U.S.'

Servicio de Información y Noticias Científicas: 'Esperamos otra gran epidemia de leishmaniasis en Sudán del Sur'

The Pharmaceutical Journal: 'R&D plan announced for drugs for neglected diseases'

Asian Scientist: 'DNDi and Eisai to develop treatment for Eumycetoma'

Jornal Brasil: 'Aporte de R $15 milhões apoiará pesquisas sobre doenças negligenciadas'

The Star Online: 'When so many lives are at stake'

Outbreak News Today: 'Sleeping sickness oral drug candidate safety study favorable'

IP Watch: 'Neglected Diseases R&D Initiative To Expand Portfolio To Hepatitis C, New Antibiotics' 'Los héroes de la lucha contra el mal de Chagas en Latinoamérica'

YAHOO! Noticias (AFP): 'Ao menos meio milhão de pessoas padecem do mal de Chagas nos EUA (DNDI)'

Nature: 'How to beat the next Ebola'

AlJazeera The Cure: 'Finding a Cure for Kala Azar'

The BMJ: 'India unlikely to meet goal of eliminating kala-azar by 2015, say experts'

El Tiempo: 'Medicamento que cura la leishmaniasis, 'made in' Colombia'
Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:  
Copyright © 2015 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202

Add us to your address book

unsubscribe from this list    update subscription preferences